SEARCH

SEARCH BY CITATION

References

  • 1
    Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998; 18:6775.
  • 2
    Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, Caldarelli R, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16:13221326.
  • 3
    Herrero C, Vicente A, Bruguera M, Ercilla MG, Barrera JM, Vidal J, Teres J, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341:788789.
  • 4
    Navas S, Bosch O, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C and B viruses infection: a retrospective study. Hepatology 1995; 21:279284.
  • 5
    Stölzel U, Köstler E, Koszka C, Stöffler-Meilicke M, Schuppan D, Somasundaram R, Doss MO, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21:15001503.
  • 6
    Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alfa therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43:529533.
  • 7
    Fernandez I, Castellano G, De Salamanca RE, Domingo MJ, Colina F, Fuertes A, Canga F, et al. Efficacy and safety of interferon therapy in patients with porphyria cutanea tarda (PCT) and chronic hepatitis C [Abstract]. J Hepatol 1998; 28:190.
  • 8
    Gibson PR, Grant J, Cronin V, Blake D, Ratnaike S. Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-alfa on porphyrin profiles in plasma, urine and faeces. J Gastroenterol Hepatol 2000; 15:192201.
  • 9
    Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22:249250.
  • 10
    Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44:525528.
  • 11
    Furata M, Kaito M, Gabazza E, Fujita N, Ishida S, Tamaki S, Ikeda R, et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 2000; 35:6062.
  • 12
    Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, Mueller C, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:12411242.
  • 13
    Christiansen L, Bygum A, Jensen A, Brandrup F, Thomsen K, Horder M, Petersen NE. Uroporphyrinogen decarboxylase gene mutations in Danish patients with porphyria cutanea tarda. Scand J Clin Lab Invest 2000; 60:611616.
  • 14
    Meguro K, Fujita H, Ishida N, Akagi R, Kurihara T, Galbraith RA, Kappas A, et al. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J Invest Dermatol 1994; 102:681685.
  • 15
    Whitby FG, Phillips JD, Kushner JP, Hill CP. Crystal structure of human uroporphyrinogen decarboxylase. EMBO J 1998; 17:24632471.
  • 16
    Bulaj ZJ, Philips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, Edwards CQ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95:15651571.
  • 17
    Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:24012407.